1141PD - Gastroenteropancreatic Neuroendocrine Tumors (GEPNET) Registry: Update from an International Collaboration

Date 29 September 2014
Event ESMO 2014
Session Neuroendocrine & endocrine tumours and CUP
Topics Neuroendocrine Cancers
Cancer Aetiology, Epidemiology, Prevention
Presenter Suayib Yalcin
Citation Annals of Oncology (2014) 25 (suppl_4): iv394-iv405. 10.1093/annonc/mdu345
Authors S. Yalcin1, S. Glasberg2, H. Abali3, F. Aykan4, L. Bai5, J. Kattan6, H.Y. Lim7, Y.S. Park8, H. Raef9, J. Ramos10, K. Rau11, S. Saglam4, S. Serdengecti12, A. Sevinc13, Y. Shan14, Y. Shyr15, V. Sriuranpong16, S.N. Turhal17, K. Yeh18, T. Hwang19
  • 1Medical Oncology, Hacettepe University Faculty of Medicine, TR-06100 - Ankara/TR
  • 2Neuroendcrine Tumor Unit, Endocrinology And Metabolism Service, The Hadassah-Hebrew University Medical Center, 91120 - Jerusalem/IL
  • 3Medical Oncology, Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., TR-01120 - Adana/TR
  • 4Medical Oncology, Istanbul University Institute of Oncology, Istanbul/TR
  • 5Medical Oncology, Chian Medical University Hospital, Taichung/TW
  • 6Dept. Of Hematology/oncology, Hotel Dieu de France Hospital, LB-1107 2020 - Beirut/LB
  • 7Dept. Medical Oncology, National Cancer Center, 169610 - Singapore/SG
  • 8Medicine, Samsung Medical Center, 135-710 - Seoul/KR
  • 9Department Of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh/SA
  • 10Hpb Surgery, Wits University Donald Gordon Medical Centre, Johannesburg/ZA
  • 11Hematology-oncology, Kaohsiung Chang Gung Memorial Hospital, 833 - Kaohsiung/TW
  • 12Division Of Medical Oncology, Department Of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, 34098 - Istanbul/TR
  • 13Medical Oncology Department, Gaziantep University Onkoloji Hastanesi, 27070 - Gaziantep/TR
  • 14Department Of Surgery, National Cheng Kung University Hospital, Tainan/TW
  • 15Department Of Surgery, Taipei Veterans General Hospital, Taipei/TW
  • 16Division Of Medical Oncology, Chulalongkorn University, Bangkok/TH
  • 17Medical Oncology, Marmara University Hospital, TR-34600 - Istanbul/TR
  • 18Oncology Department, National Taiwan University Hospital, TW-100 - Taipei/TW
  • 19Division Of General Surgery, Chang-Gang Memorial Hospital-Lin-Kou, Taoyuan/TW

Abstract

Aim

Epidemiologic data for GEPNET is lacking in many geographic areas. The aim of the GEPNET Registry is to study the prevalence, incidence, regional trends in diagnosis, and clinical management of GEPNET in the Asia-Pacific, Middle East, Turkey and South Africa.

Methods

Patients (pts) with histopathological diagnosis of GEPNET within 5 years (yrs) of registry entry were included. Pro- and retrospective data were collected at 82 sites. Enrollment in the registry was from July 2009 to December 2012. Follow-up will be for 5 yrs.

Results

As of December 1, 2013 (cut-off for this interim analysis), 1005 pts were enrolled, 933 were evaluable. At diagnosis, median age was 54 yrs [range: 12-87], gender ratio was balanced (49% male). The majority of pts (740/933, 77%) had symptoms at the time of diagnosis. Abdominal pain and weight loss were the most commonly reported symptoms. The most frequently reported primary site was the pancreas (42%) followed by the stomach (17%). The majority of pts had well-differentiated tumors (70%). Immunostaining results for Synaptophysin and Chromogranin A were reported for the majority of patients (77% and 82% respectively). Proliferative indices were less frequently reported; mitotic index: 17% and Ki-67: 50% pts. Use of computed tomography scanning was the main modality of disease evaluation (44% pts). Other imaging modalities including functional PET and octreotide scintigraphy were used in <10% pts at diagnosis. The use of serum CgA testing at diagnosis and 24 h urine 5HIAA tests were rarely used (11% and 7% pts), although there was substantial variation by geographic region. The most common initial therapy was surgery (60%) followed by somatostatin analogues (17%) and chemotherapy (16%). Median progression free survival was 57.3 months (95%CI: 52.2- 64.4), and varied by primary tumor site as well as WHO (2004) classification at diagnosis.

Conclusions

The GEPNET Registry continues to provide important information as it relates to the diagnosis and treatment of patients in the participating countries. This analysis has highlighted the need for clinical practice improvement to ensure better evaluation of patients.

Disclosure

S. Yalcin: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials. S. Glasberg: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Abali: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; F. Aykan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; L. Bai: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Kattan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H.Y. Lim: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y.S. Park: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Raef: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Ramos: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Rau: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Saglam: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Serdengecti: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; A. Sevinc: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shyr: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.; V. Sriuranpong: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S.N. Turhal: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Yeh: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; T. Hwang: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.